Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes
Lancet Diabetes Endocrinol, 10 (12), 840
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study
Int J Epidemiol (in press)